TSE:4516Pharmaceuticals
Is Nippon Shinyaku (TSE:4516) Undervalued On Its EXG 7001 Option Deal?
Nippon Shinyaku (TSE:4516) has drawn fresh investor attention after announcing an option agreement for EXG-7001, an mRNA based Duchenne muscular dystrophy therapy that could broaden its rare disease pipeline if development progresses.
See our latest analysis for Nippon Shinyaku.
Nippon Shinyaku’s latest EXG-7001 option agreement comes after a tough spell for the stock, with the share price down 21.06% over 90 days and 26.51% year to date, yet still delivering a 30.18% total shareholder return...